Contact Us

Paxil
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

Did patient hurt themselves during or after taking the drug?

Did patient become violent during or after taking the drug?

Was suicide attempted?

Was hospitalization or institutionalization required after taking antidepressant(s)?

Did loved one commit suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?

If patient did commit suicide, what was the method of suicide?

Please describe violent or suicidal behavior:

If you ever tried to stop taking Paxil and experienced withdrawal, please describe the withdrawal side effects:

Please further describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Glaxo Faces Threat of UK Class Action Over Seroxat

Dec 4, 2004 | Independent Digital UK

Lawyers acting for 1,700 people in the UK have issued a pre-action letter of claim against GlaxoSmithKline alleging serious side-effects have been suffered by their clients taking one of its best-selling drugs, the anti-depressant Seroxat.

Already, concerns over the addictive properties of Seroxat have led the UK Government to ban its prescription to people under the age of 18.

On Monday, the UK's Medicines and Healthcare Products Regulatory Agency is expected to tighten up guidelines in the use of anti-depressants after a major safety review.

The drug is also facing challenges in the US, where it is marketed as Paxil. Regulators there want its labelling changed to highlight the risk factors more fully, while lawyers are looking to claim compensation on behalf of clients.

GlaxoSmithKline said yesterday it had received a letter of claim from Hugh James Solicitors on Thursday and it was considering it in detail.

The pharmaceuticals giant's chief executive Jean-Pierre Garnier has spoken recently about the need to speed the development of other drugs, especially of a cervical cancer vaccine that he feels could be a blockbuster, because of safety concerns with other drugs.


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo